12 results for "Daniel Blockmans"
Showing 1–12 · 0.79 seconds · RSS
-
Journal Article
Diagnostic accuracy and validation of 18F-fluorodeoxyglucose positron emission tomography scores in a large cohort of patients with polymyalgia rheumatica
BackgroundSeveral studies have shown that 18F-FDG PET may contribute to the diagnosis of polymyalgia rheumatica (PMR). Previously, we developed a composite PET score called the Leuven score, which was recently adapted to the more concise Leuven/Groningen score by van der Geest et al. The aim of…
-
Journal Article
Association between vascular FDG uptake during follow-up and the development of thoracic aortic aneurysms in giant cell arteritis
BackgroundA positive PET scan at diagnosis was associated with a greater yearly increase in ascending and descending aortic diameter and thoracic aortic volume in patients with giant cell arteritis (GCA). Radiologic and histopathologic vascular abnormalities persist in a subset of treated patients…
-
Journal Article
Nodular Scleritis as Isolated Symptom of IgG4-Related Disease, Mimicking as Conjunctival Lymphoma: A Case Report
Introduction: Immunoglobulin G4-related disease (IgG4-RD) is a systemic, immune-mediated disorder marked by the infiltration of IgG4-positive plasma cells and fibrosis in affected organs. This report presents a rare case of a patient with isolated nodular scleritis as an IgG4-RD (in a more precise…
-
Journal Article
MMP-9/Gelatinase B Degrades Immune Complexes in Systemic Lupus Erythematosus
Systemic Lupus Erythematosus (SLE) is a common and devastating autoimmune disease, characterized by a dysregulated adaptive immune response against intracellular antigens, which involves both autoreactive T and B cells. In SLE, mainly intracellular autoantigens generate autoantibodies and these…
-
Journal Article
A Multicentre, Randomised, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Sirukumab in the Treatment of Giant Cell Arteritis
Abstract Introduction To evaluate the efficacy and safety of sirukumab in giant cell arteritis (GCA). Methods In this multicentre, randomised, double-blind, placebo-controlled, two-part phase 3 trial (NCT02531633; Part A [52-week double-blind treatment]; Part B [104-week follow-up]), patients with…
-
Journal Article
VEXAS syndrome: Focus on dermatological manifestations and their histopathological correlate
Abstract Background VEXAS ‘Vacuoles, E1 Enzyme, X‐linked, Autoinflammatory, Somatic syndrome’ is a rare autoinflammatory syndrome, first described in October 2020 by Beck et al. It is caused by somatic mutations in the UBA1 gene, coding for the E1 enzyme, responsible for ubiquitination. It…
-
Journal Article Full text
2022 American College of Rheumatology/EULAR classification criteria for giant cell arteritis
OBJECTIVE: To develop and validate updated classification criteria for giant cell arteritis (GCA). METHODS: Patients with vasculitis or comparator diseases were recruited into an international cohort. The study proceeded in six phases: (1) identification of candidate items, (2) prospective…
-
Journal Article Full text
2022 American College of Rheumatology/EULAR classification criteria for Takayasu arteritis